stockrow
Saturday 7 November 2026
Export ATXI’s income statement to Excel — free account
Avenue Therapeutics, Inc.
ATXI Healthcare Biotechnology
Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million.
- EPS
- −290.9%
- Free cash flow
- −169.9%
Quarter to June 2026, against a year earlier
0.43
0.03
+7.50%
Follow ATXI
Alert me
Avenue Therapeutics, Inc. (ATXI) P/E ratio
Avenue Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBLG Bone Biologics Corp. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| MLEC Moolec Science SA compare | n/m |
| JAGX Jaguar Animal Health, Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. | n/m |
| LNAI Lunai Bioworks Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)